Katayama Y, Kojima K, Omoto E, Harada M
Second Department of Internal Medicine, Okayama University Medical School, Japan.
Int J Hematol. 1996 Dec;65(1):89-92. doi: 10.1016/s0925-5710(96)00530-0.
Initial treatment with androgen (metenolone acetate) alone for 19 weeks had no effect in a 45-year-old Japanese female with refractory anemia (RA). The patient achieved trilineage hematologic recovery after addition of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin (Epo) to the androgen therapy. Anemia progressed after the cessation of metanolone acetate, but was effectively treated by the readministration of metenolone acetate. Thus, the androgen therapy in combination with hematopoietic growth factors such as G-CSF and/or Epo may be effective in patients with RA.
一名45岁的日本难治性贫血（RA）女性患者，初始单独使用雄激素（醋酸美替诺龙）治疗19周无效。在雄激素治疗中添加重组人粒细胞集落刺激因子（G-CSF）和重组人促红细胞生成素（Epo）后，患者实现了三系血液学恢复。停用醋酸美替诺龙后贫血进展，但再次给予醋酸美替诺龙可有效治疗。因此，雄激素疗法联合G-CSF和/或Epo等造血生长因子可能对RA患者有效。
